Rest-Of-Europe Ophthalmology Drugs Market Size, Share,Trends, Growth Analysis Report, 2030

Name: Rest-Of-Europe Ophthalmology Drugs Market Size, Share,Trends, Growth Analysis Report, 2030
Creator: MarketsandMarkets

Overview Request Sample Pages Request Customization Download PDF

You are viewing: Rest Of Europe Ophthalmology Drugs Market analysis

Part of: Ophthalmology Drugs Market (Global)

The Rest Of Europe Ophthalmology Drugs Market was valued at $311.8 Million in 2025 and projected to reach to $397.1 Million by 2030, representing a compound annual growth rate of 5.0%. Rest Of Europe's ophthalmology drugs market demonstrates consistent growth potential, supported by demographic shifts toward aging populations and rising prevalence of vision-threatening conditions.

Rest Of Europe Ophthalmology Drugs Market (2025-2030) : Size and Share

CAGR of

USD Million

Rest Of Europe Ophthalmology Drugs Market Trends and Insights

Rest Of Europe encompasses a diverse set of healthcare systems and regulatory environments, each contributing to steady demand for ophthalmic therapeutics across the region.
The market in Rest Of Europe is driven by an aging population, rising prevalence of age-related eye diseases, and increasing access to advanced treatment options. Rest Of Europe's ophthalmology drugs market benefits from strong healthcare infrastructure and growing investment in eye care across multiple countries.
Rest Of Europe is experiencing increased adoption of specialty ophthalmic drugs, including treatments for dry eye disease, glaucoma, and retinal conditions.
Between 2025 and 2030, Rest Of Europe will see sustained growth supported by improved diagnostic capabilities, expanding patient awareness, and the introduction of innovative therapeutic agents tailored to regional needs..

Key Market Statistics

CAGR (2025-2030) 5.0% CAGR
Market Size, 2025 ~USD 311.8 Million
Forecast, 2030 ~USD 397.1 Million
Country Rest Of Europe

Rest Of Europe Ophthalmology Drugs Market Overview

Steady Regional Growth :

Rest Of Europe's ophthalmology drugs market is expanding at a 5.0% CAGR, reaching USD 397.1 million by 2030 from USD 311.8 million in 2025, driven by aging populations and increasing prevalence of eye disorders across diverse healthcare systems.

Diverse Regulatory Landscape :

The region encompasses multiple regulatory frameworks and healthcare systems, creating varied market dynamics. Each country's unique reimbursement policies and drug approval processes influence market penetration and therapeutic adoption rates for ophthalmic medications.

Growing Demand for Ophthalmic Therapeutics :

Increasing incidence of age-related macular degeneration, diabetic retinopathy, and glaucoma across Rest Of Europe is driving sustained demand for innovative ophthalmology drugs, supported by improved diagnostic capabilities and patient awareness.

Market Consolidation Opportunities :

Fragmented healthcare systems across Rest Of Europe present opportunities for pharmaceutical companies to establish regional partnerships, expand distribution networks, and tailor treatment solutions to country-specific clinical needs and healthcare budgets.

Rest Of Europe Ophthalmology Drugs Market Dynamics

The region's diverse healthcare infrastructure creates both challenges and opportunities, with varying levels of healthcare spending and drug accessibility across different countries.
Pharmaceutical companies must navigate multiple regulatory pathways while addressing country-specific reimbursement constraints. The forecast period through 2030 indicates sustained expansion as healthcare systems increasingly prioritize eye care and invest in advanced ophthalmic therapeutics.
Growing patient awareness, improved diagnostic infrastructure, and the introduction of novel treatment modalities will drive market development.
Strategic partnerships with local healthcare providers and adaptation to regional healthcare policies will be critical for market success in Rest Of Europe..

Related Ecosystem

Pharmaceuticals

Top Technologies

Bioreactors
Analytical Testing
Bioanalytical Testing Services
Cell Counters
Data Management Services

Top Companies

Thermo Fisher Scientific Inc.
Merck KGaA
SANOFI
Pfizer Inc.
NOVARTIS

Key Takeaways

Rest Of Europe's ophthalmology drugs market is valued at USD 311.8 million in 2025 and will reach USD 397.1 million by 2030.
Rest Of Europe is experiencing a 5.0% CAGR, reflecting steady growth driven by aging demographics and increased eye disease prevalence.
Rest Of Europe's market benefits from diverse healthcare systems and strong regulatory frameworks supporting ophthalmic drug adoption.
Rest Of Europe will see accelerating demand for specialty treatments including dry eye, glaucoma, and retinal disease therapies through 2030.

Ophthalmology Drugs Market Report Scope

Report Metric	Details
Base Year	2025
Fastest Growing Segment	FARICIMAB (Molecule)
Forecast Period	2025�2030
Growth Rate	CAGR of 6.1% from 2025 to 2030
Largest Segment	INTRAVITREAL (Route Of Administration)
Market Size Base Year (Billions)	~USD 19.55 (2025)
Revenue Forecast (Billions)	~USD 26.28 (2030)
Segments Covered	Molecule, Modality, Indication, Type, Route Of Administration, End User

Rest Of Europe Ophthalmology Drugs Market Report Segmentation

6 segment dimensions are covered across the global market.

By Molecule

Aflibercept
Faricimab
Other Molecules
Ranibizumab

By Modality

Monoclonal Antibodies & Fusion Proteins
Other Modalities
Small Molecules

By Indication

Age-Related Macular Degeneration
Diabetic Macular Edema
Diabetic Retinopathy
Other Indications

By Type

Dry Amd
Wet Amd

By Route Of Administration

Intravitreal
Other Routes Of Administration
Topical

By End User

Hospitals
Long-Term Care Facilities
Specialty Centers

Target Audience

Pharmaceutical Companies : Manufacturers and distributors of ophthalmology drugs need Rest Of Europe-specific market data to develop regional commercialization strategies, optimize pricing, and identify high-potential country markets within the region.
Healthcare Investors & PE Firms : Investment professionals require detailed market sizing and growth forecasts for Rest Of Europe to evaluate acquisition opportunities, assess portfolio companies' regional performance, and identify emerging market segments.
Medical Device & Biotech Companies : Organizations developing ophthalmic solutions need regional market intelligence to understand competitive positioning, reimbursement landscapes, and partnership opportunities specific to Rest Of Europe's healthcare systems.
Healthcare Consultants & Analysts : Consulting firms and research analysts require granular Rest Of Europe market data to support client advisory work, competitive benchmarking, and strategic recommendations for pharmaceutical and healthcare clients.
Government & Healthcare Policymakers : Regional health authorities and policy organizations use market data to inform healthcare budgeting, drug approval priorities, and public health initiatives addressing ophthalmology care across Rest Of Europe.

Key Companies in the Rest Of Europe Ophthalmology Drugs Market

Company	HQ	Ownership	Strongest segments
REGENERON PHARMACEUTICALS INC.	United States	Public Company	Ophthalmology (EYLEA franchise),Immunology / Inflammation (Dupixent, Kevzara),Oncology / Hematology (Libtayo, bispecifics pipeline),
BAYER AG	Germany	Public Company	Crop Science (seeds, traits, crop protection, digital ag, services),Pharmaceuticals (cardiology, women�s health, oncology, hematology, ophthalmology, imaging, cell & gene),Consumer Health (OTC, self-care, supplements, dermatology, pain, digestive),
NOVARTIS AG	Switzerland	Public Company	Oncology and Hematology (Kisqali, Tafinlar+Mekinist, Pluvicto, Lutathera, Scemblix, Promacta/Revolade, Jakavi, Fabhalta),Cardiovascular, Renal and Metabolic (Entresto, Leqvio and related CVRM portfolio),Immunology and Neuroscience (Cosentyx, Xolair, Ilaris and related assets),
ABBVIE	United States	Public Company	Immunology (Skyrizi, Rinvoq and related),Oncology/Hematology (Imbruvica, Venclexta, Epkinly, Elahere, Emrelis),Neuroscience & CNS (Vraylar, Duodopa, Vyalev, migraine portfolio),
APELLIS PHARMACEUTICALS	United States	Private Company	SYFOVRE � Geographic Atrophy,EMPAVELI � PNH and related indications,Pipeline and collaborations (APL-3007, APL-9099, Beam partnership),
BIOGEN	United States	Public Company	Multiple sclerosis franchise (TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, OCREVUS-related),SMA and rare neurology (SPINRAZA, SKYCLARYS, QALSODY, zorevunersen pipeline linkage),Alzheimer�s and psychiatry (LEQEMBI, ZURZUVAE),
BAUSCH + LOMB	Canada	Public Company	Vision Care (contact lenses, lens care, OTC eye care, vitamins),Pharmaceuticals (Rx and generic ophthalmics),Surgical (cataract, corneal, vitreous, retinal devices and IOLs),
ASTELLAS PHARMA INC.	Japan	Public Company	Oncology (XTANDI, XOSPATA, VYLOY, PADCEV),Urology (Betanis/Myrabetriq/BETMIGA),Immunology / Transplant (Prograf),
FORMYCON AG	Germany	Public Company	Ranibizumab biosimilars (ophthalmology),Aflibercept biosimilars (ophthalmology),Ustekinumab biosimilar pipeline/early revenues,
BIOCON	India	Public Company	Biosimilars (oncology, diabetes, immunology),Generics and APIs,CRDMO (discovery, development, manufacturing services),
SANDOZ GROUP AG	Switzerland	Public Company	Small-molecule generics (oral and injectable),Biosimilars,Specialty and rare disease off-patent medicines,
SANTEN PHARMACEUTICAL CO., LTD.	Japan	Public Company	Glaucoma & ocular hypertension therapies,Dry eye & keratoconjunctival disease,Allergic conjunctivitis & inflammatory eye disease,
INNOVENT	China	Public Company	Oncology immunotherapy (PD-1, CTLA-4, combinations),Oncology targeted therapies and cell therapy,Autoimmune and ophthalmology biologics,
OUTLOOK THERAPEUTICS, INC.	United States	Public Company	ONS-5010 (ophthalmic bevacizumab for wet AMD and retinal diseases),Other pipeline / platform and collaboration-derived income,

REGENERON PHARMACEUTICALS INC.

Regeneron Pharmaceuticals Inc. is a United States-based public pharmaceutical company founded in 1988 with 15,343 employees. The company focuses on the discovery, development, and commercialization of medicines.

BAYER AG

Bayer AG is a German public company founded in 1863 with 87,757 employees, operating across pharmaceuticals, consumer health, and agricultural sciences. The company is one of the world's largest diversified life sciences organizations.

NOVARTIS AG

Novartis AG is a Swiss public pharmaceutical company founded in 1996 with 75,267 employees. The company develops and manufactures a broad range of innovative medicines and healthcare products.

ABBVIE

AbbVie is a United States-based public pharmaceutical company founded in 2012 with 57,000 employees. The company discovers, develops, and markets pharmaceutical products across multiple therapeutic areas.

APELLIS PHARMACEUTICALS

Apellis Pharmaceuticals is a United States-based private biopharmaceutical company founded in 2009 with 736 employees. The company focuses on the development of novel therapeutic candidates.

BIOGEN

Biogen is a United States-based public biotechnology company founded in 1978 with 7,500 employees. The company discovers, develops, manufactures, and delivers medicines primarily in neurology and immunology.

BAUSCH + LOMB

Bausch + Lomb is a Canadian public company founded in 1853 with 13,000 employees specializing in eye health and vision care products. The company is a global leader in the eye care industry.

ASTELLAS PHARMA INC.

Astellas Pharma Inc. is a Japanese public pharmaceutical company founded in 1923 with 14,099 employees. The company researches, develops, and commercializes pharmaceutical products worldwide.

FORMYCON AG

Formycon AG is a German public biopharmaceutical company founded in 1999 with 203 employees. The company specializes in the development of biosimilar medicines.

BIOCON

Biocon is an Indian public biopharmaceutical company founded in 1978 with 16,447 employees. The company develops and manufactures biopharmaceuticals, including biosimilars and small molecule drugs.

SANDOZ GROUP AG

Sandoz Group AG is a Swiss public pharmaceutical company founded in 1886 with 22,356 employees. The company is a global leader in generic and biosimilar medicines.

SANTEN PHARMACEUTICAL CO., LTD.

Santen Pharmaceutical Co., Ltd. is a Japanese public pharmaceutical company founded in 1890 with 3,968 employees. The company specializes in ophthalmic and other pharmaceutical products.

INNOVENT

Innovent is a Chinese public biopharmaceutical company founded in 2011 with 7,502 employees. The company focuses on the research and development of innovative biologics.

OUTLOOK THERAPEUTICS, INC.

Outlook Therapeutics, Inc. is a United States-based public biopharmaceutical company founded in 2010 with 17 employees. The company develops and commercializes ophthalmic therapeutic products.

Reasons to Buy this Report

Regional Market Sizing & Forecasting : Obtain precise market valuations specific to Rest Of Europe (USD 311.8M in 2025, USD 397.1M in 2030) with detailed CAGR analysis, enabling accurate budget allocation and revenue projections for regional operations.
Regulatory & Reimbursement Insights : Understand the diverse regulatory environments and healthcare reimbursement policies across Rest Of Europe's multiple countries, critical for product launch strategies, pricing decisions, and market entry planning.
Competitive Landscape Analysis : Identify key market players, therapeutic segments, and competitive positioning within Rest Of Europe's ophthalmology sector to inform strategic partnerships, acquisition targets, and differentiation strategies.
Growth Driver Identification : Discover region-specific factors driving the 5.0% CAGR, including aging demographics, disease prevalence trends, and healthcare infrastructure developments unique to Rest Of Europe's market dynamics.
Investment & Expansion Planning : Make informed decisions on market entry, resource allocation, and expansion priorities in Rest Of Europe based on comprehensive market data, growth forecasts, and regional opportunity assessment.

Frequently asked questions

What is the current market size of ophthalmology drugs in Rest Of Europe?

Rest Of Europe's ophthalmology drugs market is valued at USD 311.8 million in 2025.

What is the projected market size for Rest Of Europe by 2030?

Rest Of Europe's ophthalmology drugs market is projected to reach USD 397.1 million by 2030.

What is the CAGR for Rest Of Europe's ophthalmology drugs market?

Rest Of Europe's ophthalmology drugs market is growing at a CAGR of 5.0% from 2025 to 2030.

What are the primary drivers of growth in Rest Of Europe's ophthalmology drugs market?

Rest Of Europe's market growth is driven by an aging population, rising prevalence of age-related eye diseases, improved diagnostic capabilities, and increased adoption of specialty ophthalmic treatments.

Which therapeutic areas are experiencing the most growth in Rest Of Europe?

Rest Of Europe is seeing strong growth in dry eye disease, glaucoma, and retinal condition treatments, supported by expanding patient awareness and innovative drug introductions.

RESEARCH METHODOLOGY

This research study extensively used secondary sources, directories, and databases to identify and collect valuable information to analyze the global ophthalmology drugs market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the ophthalmology drugs market. The secondary sources used for this study include US Food and Drug Administration (US FDA), European Medicines Agency (EMA), World Health Organization (WHO), National Center for Biotechnology Information (NCBI), White papers, Company Websites, Interviews with Experts, Annual Reports, SEC Filings, Investor Presentations, and MarketsandMarkets Analysis. These sources also obtained key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

Primary Research

A comprehensive primary research was undertaken following an initial assessment of the global ophthalmology drugs market landscape through secondary research. This involved conducting in-depth interviews with market experts from the demand side, including stakeholders from hospitals, long-term care facilities, and specialty centers. Additionally, interviews were held with key supply-side participants, such as C-suite and senior executives, product managers, and marketing and sales leaders from prominent manufacturers, distributors, and channel partners. The research covered six major geographical regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 70% of the primary interviews were conducted with supply-side participants, while 30% involved demand-side experts. Data collection methods included structured questionnaires, email correspondence, online surveys, personal interviews, and telephonic discussions to understand the market dynamics comprehensively.

The following is a breakdown of the primary respondents:

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both bottom-up and top-down approaches were used to estimate and validate the total size of the ophthalmology drugs market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

A list of the major global players operating in the ophthalmology drugs market was generated.
The revenues generated from their ophthalmology drug products have been determined through annual reports and secondary sources (including paid databases).
The products were mapped according to the segments of the market. Percentage shares and splits were determined based on the revenue contributed to each segment. This was verified using secondary sources and by industry experts.
All assumptions, approaches, and individual shares/revenue estimates were validated through expert interviews.

Global Ophthalmology Drugs Market Size: Bottom-up and Top-down Approaches

Data Triangulation

After arriving at the market size from the estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

Ophthalmology drugs are specifically designed to treat or prevent eye diseases and disorders. These medications target various parts of the eye, including the cornea, conjunctiva, lens, retina, and optic nerve. The market includes a range of effective therapies across different drug modalities, such as biologics and biosimilars (e.g., anti-VEGF drugs, monoclonal antibodies, oligonucleotides, and peptides), small molecules, gene therapy, and cell therapy. These treatments address various conditions, including age-related macular degeneration (AMD), diabetic retinopathy, diabetic macular edema, retinal vein occlusion, uveitis, and neurotrophic keratitis, among others.

Stakeholders

Pharmaceutical & biotechnology companies
Hospitals
Patient advocacy organizations
Specialty clinics
Long-term care facilities
Academic researchers and government research organizations
Private research institutes
Contract manufacturing organizations (CMOs)
Contract research organizations (CROs)
Venture capitalists

Report Objectives

To define, describe, and forecast the ophthalmology drugs market by molecule, modality, route of administration, indication, end user, and region
To provide detailed information regarding the factors influencing market growth (such as drivers, opportunities, restraints, and challenges)
To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall ophthalmology drugs market
To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
To profile the key players in the global ophthalmology drugs market as well as comprehensively analyze their core competencies and market rankings
To forecast the size of the market segments in North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
To track and analyze competitive developments, such as product launches & approvals, expansions, acquisitions, partnerships, product pipelines, collaborations, and agreements, in the ophthalmology drugs market

Get the Full Ophthalmology Drugs Market Report

Full forecast, segment splits, and company analysis for all Ophthalmology Drugs Market.

Download Sample Pages Buy Report

REPORT COVERAGE

＋

Report Description
Market Overview
Market Dynamics
Related Ecosystem
Key Takeaways
Market Scope
Report Segmentation
Target Audience
Key Companies

Market Size in	USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered	Value (USD MN)